Novo closing in on the Holy Grail
![Foto: Merrion Pharmaceuticals / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article3255910.ece/ALTERNATES/schema-16_9/Merrion_Facility.jpg)
Novo Nordisk CEO Lars Rebien Sørensen has called the search for an insulin pill “the greatest single research effort in the company at the moment” and many observers agree that orally-administered insulin is the Holy Grail for drug companies operating on the global diabetes market.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Rebien: The strongest pipeline ever
For abonnenter
An alternative to the needle
For abonnenter
Novo-VP: Now we dream of the ultimate step
For abonnenter